Nutritional composition and nutritional food for improving premature delivery retinopathy

Abstract

The invention relates to the technical field of nutritional food, and particularly discloses a nutritional composition and nutritional food for improving premature delivery retinopathy. The nutritional composition for improving the premature retinopathy is prepared from the following components in parts by mass: 0.05 to 0.3 part of casein phosphopeptide, 0.05 to 0.3 part of casein glycomacropeptide, 1.5 to 3 parts of polydextrose and 0.1 to 3 parts of fructo-oligosaccharide. The nutritional composition provided by the invention can improve the abundance of beneficial bacteria bifidobacteria in intestinal tracts, reduce the abundance of enterobacter, reduce the neovascularization area of pathological retina caused by high oxygen, and reduce the area of a blood-vessel-free region; the retina-intestinal axis double-direction regulating effect inhibits or prevents the oxidation process, then retinal cells are protected against oxidative stress damage, and the retina-intestinal axis double-direction regulating compound can be used in the fields of formula food with special medical purposes, health food, infant formula food, common food and the like and has good market application value.

Description

Technical Field

[0001] The present invention relates to the technical field of nutritional foods, and in particular to a nutritional composition and nutritional food for improving retinopathy of prematurity. Background Art

[0002] Retinopathy of prematurity (ROP) is a serious complication in premature infants, caused by the loss of normal blood vessels in the immature retina and the appearance of new pathological blood vessels and fibrosis. It is more common in low birth weight infants and small gestational age premature infants. In recent years, thanks to the continuous improvement in the rescue, treatment and care of critically ill premature infants, the survival rate of extremely low birth weight infants and very low birth weight infants has been rising in a straight line. Among them, many extremely premature infants and very low birth weight infants between 22 weeks and 24 weeks have been successfully treated. However, along with the increase in their survival rate, the incidence of retinopathy of prematurity is also increasing year by year.

[0003] Treatments for retinopathy of prematurity are mostly surgical and non-surgical. Surgical treatments include laser photocoagulation, scleral cerclage, vitrectomy, etc., while non-surgical treatments are most commonly treated with anti-VEGF (vascular endothelial growth factor) drugs. Currently, in the field of food for premature infants and low birth weight infants, such as special medical formula powder, infant formula powder, complementary food and nutritional supplements, no existing technology has been found to protect retinal cells from oxidative stress damage by inhibiting or preventing the oxidation process through bidirectional regulation of the retinal-gut axis. Summary of the invention

[0004] In order to solve the problem of how to improve retinopathy of prematurity, the present invention provides a nutritional composition and a nutritional food for improving retinopathy of prematurity. By controlling the components and dosages of the nutritional composition, the retinopathy problem of premature infants and low birth weight infants can be significantly improved.

[0005] In order to solve the above technical problems, the technical solution provided by the present invention is: In a first aspect, the present invention provides a nutritional composition for improving retinopathy of prematurity, comprising the following components in parts by weight: 0.05 to 0.3 parts of casein phosphopeptide, 0.05 to 0.3 parts of casein glycomacropeptide, 1.5 to 3 parts of polydextrose, and 0.1 to 3 parts of oligofructose.

[0006] Compared with the prior art, the nutritional composition for improving retinopathy of prematurity provided by the present invention can inhibit or prevent the oxidation process through the bidirectional regulation of the retina-gut axis and thus protect retinal cells from oxidative stress damage. Experimental data show that casein glycomacropeptide can improve intestinal flora and reduce oxidative stress, polydextrose can improve intestinal flora, and the components work synergistically to improve retinopathy caused by premature retinal damage caused by oxidative stress; the nutritional composition provided by the present invention can increase the abundance of beneficial bacteria bifidobacteria in the intestine, reduce the abundance of enterobacteria, and at the same time reduce the area of ​​new blood vessels of pathological retina caused by high oxygen, and reduce the area of ​​avascular area.

[0007] Preferably, the nutritional composition comprises the following components in parts by weight: 0.1 to 0.3 parts of casein phosphopeptide, 0.1 to 0.2 parts of casein glycomacropeptide, 1.8 to 2.5 parts of polydextrose and 0.1 to 1.2 parts of oligofructose.

[0008] Preferably, the nutritional composition further comprises: protein, fat and carbohydrates.

[0009] Further preferably, the nutritional composition further comprises the following components in parts by weight: 10 to 21 parts of protein, 22 to 41 parts of fat, and 47 to 70 parts of carbohydrates.

[0010] More preferably, the nutritional composition further comprises the following components in parts by weight: 12 to 17 parts of protein, 25 to 30 parts of fat, and 50 to 58 parts of carbohydrates.

[0011] Further preferably, the protein comprises at least one of skimmed milk powder, isolated whey protein, concentrated whey protein or concentrated milk protein.

[0012] Further preferably, the fat comprises at least one of soybean oil, sunflower oil, coconut oil, rapeseed oil, corn oil or medium chain triglycerides.

[0013] Further preferably, the carbohydrate comprises at least one of desalted whey powder or lactose.

[0014] In a second aspect, the present invention provides a method for preparing the nutritional composition for improving retinopathy of prematurity, comprising the following steps: The components are weighed according to the designed mass ratio and mixed evenly to obtain a nutritional composition for improving retinopathy of prematurity.

[0015] In a third aspect, the present invention provides a nutritious food, comprising the nutritious composition for improving retinopathy of prematurity.

[0016] Preferably, the nutritional food also includes vitamins and minerals.

[0017] Further preferably, the vitamins and minerals include the following components: vitamin A 299 μg RE / 100g~3781 μg RE / 100g, vitamin D 3 5μg / 100g~47μg / 100g, Vitamin E 3mg α-TE / 100g~51mg α-TE / 100g, Vitamin K 1 21μg / 100g~139μg / 100g, Vitamin B 1 299μg / 100g~1538μg / 100g, Vitamin B 2 406μg / 100g~3161μg / 100g, Vitamin B 6 182μg / 100g~1062μg / 100g, Vitamin B 12 0.5μg / 100g~8μg / 100g, niacin 1.5mg / 100g~25.5mg / 100g, folic acid 53μg / 100g~459μg / 100g, pantothenic acid 2.1mg / 100g~10.2mg / 100g, vitamin C 53mg / 100g~363mg / 100g, biotin 3μg / 100g~51μg / 100g, inositol 21mg / 100g~378mg / 100g, sodium 107mg / 100g~534mg / 100g, potassium 299mg / 100g~918mg / 100g, copper 182μg / 100g~1277μg / 100g, magnesium 26mg / 100g~88mg / 100g, iron 2mg / 100g~19mg / 100g, zinc 3mg / 100g~14mg / 100g, manganese 26μg / 100g~5 13μg / 100g, calcium 256mg / 100g~1282mg / 100g, phosphorus 128mg / 100g~641mg / 100g, iodine 53μg / 100g~299μg / 100g, chlorine 256mg / 100g~1153mg / 100g, selenium 10μg / 100g~46μg / 100g, choline 36mg / 100g~256mg / 100g, taurine 0~64mg / 100g, L-carnitine 6mg / 100g~100mg / 100g and nucleotides 12mg / 100g~58mg / 100g.

[0018] The nutritional composition provided by the present invention can be applied to the fields of formula food for special medical purposes, health food, infant formula food and general food. All components of the nutritional food in the present invention can be mixed by dry mixing process. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1The sequence proportion of Enterobacter in the feces of each group of young mice in the present invention is shown; Figure 2 The sequence proportion diagram of bifidobacteria in the feces of each group of young mice in the present invention; Figure 3 The figure is a graph showing the percentage of the avascular area in the retina of each group of young mice of the present invention; Figure 4 The figure is a graph showing the percentage of the area of ​​the neovascularization zone in the retina of each group of young mice of the present invention; Figure 5 is the SOD activity in the retinal tissue of each group of young mice of the present invention; Figure 6 is the MDA content in the retinal tissue of each group of young mice in the present invention; In the figure, the same letters indicate no significant difference, and different letters indicate significant difference (P < 0.05). DETAILED DESCRIPTION

[0020] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0021] In the present invention, materials not otherwise specified are all commercially available products.

[0022] Example 1 The present embodiment provides a nutritional composition for improving retinopathy of prematurity, comprising the following components by mass: 0.05 g of casein phosphopeptide, 0.05 g of casein glycomacropeptide, 1.5 g of polydextrose, 0.1 g of oligofructose, 14 g of protein (provided by an equal mass of concentrated whey protein and concentrated milk protein), 30 g of fat (provided by an equal mass of soybean oil and sunflower oil), and 50 g of carbohydrates (provided by an equal mass of desalted whey powder and lactose).

[0023] The dry mixing process is adopted to evenly mix the components of the nutritional composition for improving retinopathy of prematurity.

[0024] Example 2 This embodiment provides a nutritional composition for improving retinopathy of prematurity, including the following components by mass: 0.2g casein phosphopeptide, 0.2g casein glycomacropeptide, 2.1g polydextrose, 0.7g oligofructose, 14g protein (same mass provided by skim milk powder and whey protein isolate), 27g fat (same mass provided by coconut oil, corn oil and medium chain triglycerides), and 53g carbohydrate (same mass provided by desalted whey powder and lactose in a mass ratio of 5:1). The total energy of protein, fat and carbohydrate is about 2138kJ.

[0025] The dry mixing process is adopted to evenly mix the components of the nutritional composition for improving retinopathy of prematurity.

[0026] Example 3 This embodiment provides a nutritional composition for improving retinopathy of prematurity, comprising the following components by mass: 0.3 g of casein phosphopeptide, 0.1 g of casein glycomacropeptide, 3 g of polydextrose, 3 g of oligofructose, 17 g of protein (provided by equal masses of skim milk powder and concentrated milk protein), 25 g of fat (equal masses of soybean oil, coconut oil and rapeseed oil), and 52 g of carbohydrates (provided by desalted whey powder).

[0027] The dry mixing process is adopted to evenly mix the components of the nutritional composition for improving retinopathy of prematurity.

[0028] Comparative Example 1 This comparative example provides a nutritional composition, which is similar to Example 2, except that casein phosphopeptide is replaced with casein glycomacropeptide of the same mass, that is, the amount of casein glycomacropeptide is 0.4 g. The remaining conditions are the same as those in Example 2 and will not be described in detail.

[0029] Comparative Example 2 This comparative example provides a nutritional composition, which is similar to Example 2, except that the casein glycomacropeptide is replaced with casein phosphopeptide of the same mass, that is, the amount of casein phosphopeptide is 0.4 g. The remaining conditions are the same as those in Example 2 and will not be described in detail.

[0030] Comparative Example 3 This comparative example provides a nutritional composition, which is similar to Example 2, except that polydextrose is replaced with oligofructose of the same mass, that is, the amount of oligofructose is 2.8 g. The remaining conditions are the same as those in Example 2 and will not be described in detail.

[0031] Comparative Example 4 This comparative example provides a nutritional composition, which is similar to Example 2, except that oligofructose is replaced with polydextrose of the same mass, that is, the amount of polydextrose is 2.8 g. The remaining conditions are the same as those in Example 2 and will not be described in detail.

[0032] Comparative Example 5 This comparative example provides a nutritional composition, which is similar to Example 2, except that: casein phosphopeptide, casein glycomacropeptide, polydextrose and oligofructose are omitted at the same time. The remaining conditions are the same as those in Example 2, that is, the nutritional composition includes the following components by mass: protein (provided by equal mass of skim milk powder and isolated whey protein) 14g, fat (provided by equal mass of coconut oil, corn oil and medium-chain triglycerides) 27g and carbohydrate (provided by desalted whey powder and lactose in a mass ratio of 5:1) 53g. The total energy of protein, fat and carbohydrate is about 2138kJ.

[0033] Application Examples 1~3 Application Examples 1 to 3 provide a nutritional food, respectively, consisting of a nutritional composition for improving retinopathy of prematurity and vitamins and minerals. The nutritional composition is respectively the nutritional composition for improving retinopathy of prematurity of Examples 1 to 3. The vitamins and minerals include the following components: vitamin A 530 μg RE / 100g, vitamin D 3 16μg / 100g, Vitamin E 12mg α-TE / 100g, Vitamin K 1 35μg / 100g, Vitamin B 1 700μg / 100g, Vitamin B 2 1064μg / 100g, Vitamin B 6 630μg / 100g, Vitamin B 12 1.9μg / 100g, niacin 7.5mg / 100g, folic acid 150μg / 100g, pantothenic acid 5mg / 100g, vitamin C 110mg / 100g, biotin 18μg / 100g, inositol 88mg / 100g, sodium 290mg / 100g, potassium 501mg / 100g, copper 430μg / 100g, magnesium 50mg / 100g, iron 8.5mg / 100g, zinc 5.5mg / 100g, manganese 53μg / 100g, calcium 589mg / 100g, phosphorus 342mg / 100g, iodine 93μg / 100g, chlorine 440mg / 100g, selenium 12.8μg / 100g, choline 83mg / 100g, taurine 33mg / 100g, L-carnitine 10.8mg / 100g and nucleotides 21mg / 100g.

[0034] The dry mixing process is adopted to uniformly mix the components of the above-mentioned nutritious food.

[0035] Application Comparative Examples 1 to 5 Comparative Examples 1 to 5 provide a nutritious food, respectively, consisting of a nutritious composition and vitamins and minerals. The nutritious compositions are respectively the nutritious compositions of Comparative Examples 1 to 5. The components and contents of the vitamins and minerals are the same as those of Application Example 1, and are not described in detail.

[0036] The dry mixing process is adopted to uniformly mix the components of the above-mentioned nutritious food.

[0037] Efficacy trials (1) Animal model establishment and grouping Healthy adult SD pregnant mice were used in the experiment, provided by Sibeifu (Suzhou) Biological Co., Ltd. (China), with a certificate number of SCXK (Suzhou) 2022-0006, a gestational age of 12d~14d, and a body weight of 450g~550g. Before the experiment, each pregnant mouse was placed in a separate mouse box to adapt to the environment for 3d~5d, with free access to water and food. The experimental environmental conditions included: a light / dark cycle of 12h / 12h, a background noise of 40db±10db, and a room temperature of 20℃~24℃. The gestation period of normal rats is 19d~23d, and the pups born before the 20th day of pregnancy are defined as premature pups.

[0038] Preterm birth model was established in pregnant mice by lipopolysaccharide (LPS) to induce premature birth. On the 16th day of pregnancy, the weight of the pregnant mice was accurately weighed and LPS (purchased from Thermo Fisher Scientific) was intraperitoneally injected at a dose of 350 μg / kg for 2 consecutive days.

[0039] 10 to 12 premature mice from each litter were included in the subsequent experiment, with a total of 60 to 70 mice, which were randomly divided into 6 groups, with 10 mice in each group. Each group was fed for 30 days, and the feed formula of each group was the nutritious food of Application Examples 1 to 3 and Application Comparative Examples 1 to 5.

[0040] Within 6 hours after birth, the newborn premature mice were placed in a closed oxygen box with an oxygen concentration of 80% (hyperoxia), alternating every 24 hours for 14 days. At 15 days, the mice were placed in normal air and continued to be raised until 30 days after birth. A digital oxygen meter was used to monitor the oxygen concentration in the oxygen box, at least 5 times a day, with an oxygen flow rate of 2L / min~3L / min and a nitrogen flow rate of 0.5L / min~0.8L / min, so that the oxygen concentration in the oxygen box during the hyperoxia period was maintained at 80%±2%.

[0041] (2) Fecal 16S rRNA fecal intestinal flora sequencing On the 30th day of feeding, the feces of the six groups of pups were collected. Before collecting feces each time, each pup was placed in a sterilized animal cage and allowed to move freely for 30 minutes. About 0.2 g of feces was collected from each pup, and bacterial DNA was extracted from the feces of each group of pups according to the instructions of the QIAGEN fecal genomic DNA extraction kit. Then, universal primers 341F and 805R were used for PCR amplification in the 16SrRNA V3-V4 hypervariable region. After quantitative detection of the amplified products by 2% agarose gel electrophoresis, high-throughput sequencing of the 16S rRNA gene was performed to obtain the proportion of Enterobacter and Bifidobacterium sequences. The test results are as follows: Figure 1~Figure 2 As shown in Table 1.

[0042] Table 1 The sequence proportions of Enterobacteriaceae and Bifidobacteria in the feces of each group of young mice

[0043] In each column of Table 1, the same letters indicate no significant difference, and different letters indicate significant difference (P < 0.05).

[0044] Depend on Figure 1 As can be seen from Table 1, the proportion of Enterobacter sequences in groups 1 to 4 of application examples is significantly lower than that in group 5 of application example, indicating that adding casein phosphopeptide, casein glycomacropeptide, polydextrose or oligofructose to nutritious food can regulate the number of Enterobacter; the proportion of Enterobacter sequences in group 2 of application example is higher than that in groups 1 and 3 to 4 of application examples, indicating that the reduction of casein glycomacropeptide weakens the regulating effect of intestinal flora; the proportion of Enterobacter sequences in groups 3 to 4 of application examples is lower than that in groups 1 to 2 of application examples, indicating that oligofructose and polydextrose have a greater impact on Enterobacter; the proportion of Enterobacter sequences in groups 1 to 3 of application examples is significantly lower than that in groups 1 to 5 of application examples, indicating that the nutritious food provided by the present invention can effectively regulate the number of Enterobacter.

[0045] Depend on Figure 2 As can be seen from Table 1, the proportion of bifidobacterium sequences in application examples 1 to 4 groups was significantly higher than that in application example 5 group, indicating that adding casein phosphopeptide, casein glycomacropeptide, polydextrose or oligofructose to nutritious food can regulate the number of bifidobacteria; among the application examples 1 to 4 groups, the proportion of bifidobacterium sequences in application example 2 group was the lowest, indicating that the reduction of casein glycomacropeptide weakened the regulatory effect of intestinal flora; the proportion of bifidobacterium sequences in application examples 1 to 3 groups was significantly higher than that in application examples 1 to 5 groups, indicating that the nutritious food provided by the present invention can effectively regulate the number of bifidobacteria.

[0046] The nutritious food provided by the invention can reduce the number of enterobacteria and increase the number of bifidobacteria, thereby effectively improving retinopathy of premature infants through microbial regulation.

[0047] (3) The size of the avascular and neovascular areas in the retina of young mice After 30 days of feeding, the young mice in each group were killed, and one eye was randomly selected to remove the retinal debris and residual vitreous blood vessels for retinal flat mount. The retinal flat mount was placed on a poly-lysine-coated slide with the inner layer of the retina facing up, sealed with 50% glycerol, covered with a cover glass, and stored at 4°C in the dark.

[0048] The blood vessels were stained, and the stained slides were observed under a fluorescence microscope and photographed. The retinal blood vessels were green fluorescent, and the avascular area was the black area where the peripheral green fluorescence terminated. Adobe Photoshop CS3 image analysis software was used to measure and calculate the percentage of the avascular area and the area of ​​the neovascular area to the total retinal area. The test results are shown in Figure 2. Figure 3~Figure 4 As shown in Table 2.

[0049] Table 2 The percentage of avascular area and neovascular area in the retina of each group of young mice

[0050] In each column of Table 2, the same letters indicate no significant difference, and different letters indicate significant difference (P < 0.05).

[0051] Depend on Figure 3 As can be seen from Table 2, the proportion of the avascular area in application examples 1 to 3 groups is smaller than that in application comparison examples 1 to 5 groups, and the proportion in application comparison example 5 group is the highest, and is significantly different from application comparison examples 1 to 4 and application examples 1 to 3 groups. Figure 4 As can be seen from Table 2, the proportion of the neovascularization area in application example groups 1 to 3 is smaller than that in application comparison examples 1 to 5, and the proportion in application comparison example 5 is the highest. This indicates that the nutritious food provided by the present invention can effectively reduce the avascular area of ​​the immature retina and reduce the pathological neovascularization caused by hyperoxia.

[0052] In addition, the retinal vascular performance of the comparative example 3-4 group was better than that of the comparative example 1-2 group, but the difference was not significant. The difference was that the comparative example 3-4 group contained casein glycomacropeptide and casein phosphopeptide at the optimal content, which indicates that the two components of casein glycomacropeptide and casein phosphopeptide and their content in nutritional foods may have more effects.

[0053] (4) Determination of oxidative stress markers The retinal blood vessels of premature infants are not fully developed and mature. Hyperoxia can cause vasoconstriction in the immature retina, leading to retinal hypoxia-ischemia and vascular occlusion, which in turn produces a large amount of vascular growth factors. Driven by the retinal VEGF signaling pathway, pathological retinal neovascularization and fibrosis are formed, leading to retinal detachment and blindness. Oxidative stress is one of the important injury mechanisms of ROP. The oxidative stress level of premature infants can be used as a predictor of ROP, and the severity of ROP increases with the increase of oxidative stress. Superoxide dismutase (SOD) and 3,4-methylenedioxyiminoamphetamine (MDA) are very sensitive markers of oxidative stress. Kits were used to determine SOD activity and MDA content. The SOD kit used a total superoxide dismutase (T-SOD) test kit (hydroxylamine method), and the MDA kit used a malondialdehyde (MDA) assay kit (TBA method), both of which were purchased from Nanjing Jiancheng Bioengineering Institute.

[0054] The retina of the other eyeball of each group of young mice was quickly separated under a microscope, and PBS buffer was added at a mass volume ratio of 1g:9mL of retina to phosphate buffered saline (PBS buffer), and the retina was fully ground to prepare a homogenate. The retina was centrifuged at 3500r / min for 10min in a 4℃ low-temperature centrifuge, and the supernatant was taken and stored at -80℃. The SOD activity and MDA content in the retinal tissue of each group of young mice were determined strictly according to the instructions of the SOD and MDA kits. The test results are shown in Figure 5~Figure 6 As shown in Table 3.

[0055] Table 3 Test results of SOD activity and MDA content in retinal tissue of young mice in each group

[0056] In each column of Table 3, the same letters indicate no significant difference, and different letters indicate significant difference (P < 0.05).

[0057] Depend on Figure 5 As can be seen from Table 3, the SOD activity of application examples 1 to 3 is higher than that of application comparison examples 1 to 5, and the SOD activity of application comparison example 5 is the lowest, and is significantly different from the other groups. Figure 6 As can be seen from Table 3, the MDA content of application examples 1 to 3 groups is significantly lower than that of application comparison examples 1 to 5 groups, and the MDA content of application comparison example 5 group is the highest, and is significantly different from other groups. This shows that the intake of the nutritious food provided by the present invention can effectively regulate the degree of oxidative stress. In addition, the SOD value of application comparison example 1 to 2 groups is significantly lower than that of application comparison example 3 to 4 groups, and the MDA content of application comparison example 1 to 2 groups is significantly higher than that of application comparison example 3 to 4 groups, which shows that compared with polydextrose or oligofructose, the absence of casein phosphopeptide or casein glycomacropeptide weakens the anti-oxidative stress effect.

[0058] The comprehensive results show that the nutritional food provided by the present invention with the nutritional composition as the main active ingredient can inhibit or prevent the oxidation process through the bidirectional regulation of the retina-gut axis and thus protect retinal cells from oxidative stress damage.

[0059] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A nutritional composition for improving retinopathy of prematurity, characterized in that: The invention comprises the following components in parts by weight: 0.05 to 0.3 parts of casein phosphopeptide, 0.05 to 0.3 parts of casein glycomacropeptide, 1.5 to 3 parts of polydextrose and 0.1 to 3 parts of oligofructose.

2. The nutritional composition for improving retinopathy of prematurity according to claim 1, characterized in that: The nutritional composition comprises the following components in parts by weight: 0.1 to 0.3 parts of casein phosphopeptide, 0.1 to 0.2 parts of casein glycomacropeptide, 1.8 to 2.5 parts of polydextrose and 0.1 to 1.2 parts of oligofructose.

3. The nutritional composition for improving retinopathy of prematurity according to claim 1, characterized in that: The nutritional composition further comprises: protein, fat and carbohydrate.

4. The nutritional composition for improving retinopathy of prematurity according to claim 1 or 3, characterized in that: The nutritional composition further comprises the following components in parts by weight: 10 to 21 parts of protein, 22 to 41 parts of fat, and 47 to 70 parts of carbohydrates.

5. The nutritional composition for improving retinopathy of prematurity according to claim 4, characterized in that: The nutritional composition further comprises the following components in parts by weight: 12 to 17 parts of protein, 25 to 30 parts of fat, and 50 to 58 parts of carbohydrates.

6. The nutritional composition for improving retinopathy of prematurity according to claim 3, characterized in that: The protein comprises at least one of skim milk powder, isolated whey protein, concentrated whey protein or concentrated milk protein.

7. The nutritional composition for improving retinopathy of prematurity according to claim 3, characterized in that: The fat comprises at least one of soybean oil, sunflower oil, coconut oil, rapeseed oil, corn oil or medium chain triglycerides; The carbohydrate comprises at least one of demineralized whey powder or lactose.

8. A nutritional food, characterized in that: A nutritional composition for improving retinopathy of prematurity comprising the composition described in any one of claims 1 to 7.

9. The nutritional food according to claim 8, characterized in that The nutritional food also includes vitamins and minerals.

10. The nutritional food according to claim 9, characterized in that The vitamin minerals include the following components: vitamin A 299μg RE / 100g~3781μg RE / 100g, vitamin D3 5μg / 100g~47μg / 100g, vitamin E3mg α-TE / 100g~51mg α-TE / 100g, vitamin K121μg / 100g~139μg / 100g, vitamin B1 299μg / 100g~1538μg / 100g, vitamin B2 406μg / 100g~3161μg / 100g, vitamin B6 182μg / 100g~1062μg / 100g, vitamin B 12 0.5μg / 100g~8μg / 100g, niacin 1.5mg / 100g~25.5mg / 100g, folic acid 53μg / 100g~459μg / 100g, pantothenic acid 2.1mg / 100g~10.2mg / 100g, vitamin C 53mg / 100g~363mg / 100g, biotin 3μg / 100g~51μg / 100g, inositol 21mg / 100g~378mg / 100g, sodium 107mg / 100g~534mg / 100g, potassium 299mg / 100g~918mg / 100g, copper 182μg / 100g~1277μg / 100g, magnesium 26mg / 100g~88mg / 100g, iron 2mg / 100g~19mg / 100g, zinc 3mg / 100g~14mg / 100g, manganese 26μg / 100g~5 13μg / 100g, calcium 256mg / 100g~1282mg / 100g, phosphorus 128mg / 100g~641mg / 100g, iodine 53μg / 100g~299μg / 100g, chlorine 256mg / 100g~1153mg / 100g, selenium 10μg / 100g~46μg / 100g, choline 36mg / 100g~256mg / 100g, taurine 0~64mg / 100g, L-carnitine 6mg / 100g~100mg / 100g and nucleotides 12mg / 100g~58mg / 100g.

Images